-
Something wrong with this record ?
Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary
J. Vrbikova, K. Dvorakova , M. Hill, L. Starka
Language English Country Slovakia
Document type Clinical Trial, Research Support, Non-U.S. Gov't
PubMed
17201585
Knihovny.cz E-resources
- MeSH
- Androgens blood MeSH
- Contraception MeSH
- Cyproterone Acetate therapeutic use MeSH
- Adult MeSH
- Estrogens MeSH
- Ethinyl Estradiol therapeutic use MeSH
- Drug Combinations MeSH
- Weight Gain drug effects MeSH
- Contraceptives, Oral, Hormonal * therapeutic use MeSH
- Humans MeSH
- Lipids blood MeSH
- Polycystic Ovary Syndrome * MeSH
- Body Weight drug effects MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
Objective. The aim of this study was to investigate the effect of oral contraceptive Diane 35 (ethinylestradiol + cyproteroneacetate – EE/CPA) which is widely used in the treatment of PCOS in Europe, on body weight, lipid levels and endocrine parameters in non-obese women with PCOS. Subjects and methods. Nineteen PCOS women were examined in the early follicular phase of menstrual cycle, blood samples for the estimation of cholesterol (C), HDL cholesterol (HDL-C), triglycerides (TG), testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS) and sex hormone binding globulin (SHBG) were taken before the start of treatment with Diane 35 and again after 7 ± 3.8 months of treatment with Diane 35. Body weight (W) was recorded at the time of both examinations. Results. After the treatment with Diane 35 the levels of W (p options for PCOS, besides contraception. Studies concerning body composition during contraceptive treatment in PCOS would be also useful in the future.
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19002154
- 003
- CZ-PrNML
- 005
- 20190225160246.0
- 007
- ta
- 008
- 190111s2006 xo d f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)17201585
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Vrbíková, Jana, $d 1964- $7 jo20000074106 $u Institute of Endocrinology, Prague, Czech Republic
- 245 10
- $a Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary / $c J. Vrbikova, K. Dvorakova , M. Hill, L. Starka
- 504 __
- $a Literatura
- 520 3_
- $a Objective. The aim of this study was to investigate the effect of oral contraceptive Diane 35 (ethinylestradiol + cyproteroneacetate – EE/CPA) which is widely used in the treatment of PCOS in Europe, on body weight, lipid levels and endocrine parameters in non-obese women with PCOS. Subjects and methods. Nineteen PCOS women were examined in the early follicular phase of menstrual cycle, blood samples for the estimation of cholesterol (C), HDL cholesterol (HDL-C), triglycerides (TG), testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS) and sex hormone binding globulin (SHBG) were taken before the start of treatment with Diane 35 and again after 7 ± 3.8 months of treatment with Diane 35. Body weight (W) was recorded at the time of both examinations. Results. After the treatment with Diane 35 the levels of W (p options for PCOS, besides contraception. Studies concerning body composition during contraceptive treatment in PCOS would be also useful in the future.
- 650 _2
- $a androgeny $x krev $7 D000728
- 650 _2
- $a tělesná hmotnost $x účinky léků $7 D001835
- 650 _2
- $a antikoncepce $7 D003267
- 650 12
- $a kontraceptiva orální hormonální $x terapeutické užití $7 D003278
- 650 _2
- $a cyproteronacetát $x terapeutické užití $7 D017373
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a ethinylestradiol $x terapeutické užití $7 D004997
- 650 _2
- $a estrogeny $7 D004967
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 12
- $a syndrom polycystických ovarií $7 D011085
- 650 _2
- $a hmotnostní přírůstek $x účinky léků $7 D015430
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dvořáková, Kateřina $7 xx0070717 $u Institute of Endocrinology, Prague, Czech Republic
- 700 1_
- $a Hill, Martin, $d 1962- $7 mzk2005304431 $u Institute of Endocrinology, Prague, Czech Republic
- 700 1_
- $a Stárka, Luboslav, $d 1930- $7 jn19990209795 $u Institute of Endocrinology, Prague, Czech Republic
- 773 0_
- $t Endocrine regulations $x 1210-0668 $g Roč. 40, č. 4 (2006), s. 119-123 $w MED00001518
- 910 __
- $a ABA008 $b A 3699 $c 152 a $y 4 $z 0
- 990 __
- $a 20190111084116 $b ABA008
- 991 __
- $a 20190225160548 $b ABA008
- 999 __
- $a ok $b bmc $g 1366491 $s 1040287
- BAS __
- $a 3
- BMC __
- $a 2006 $b 40 $c 4 $d 119-123 $i 1210-0668 $m Endocrine regulations $x MED00001518
- LZP __
- $c NLK182 $d 20190225 $a NLK 2019-04/pk
